Merus Clears Wall Street's Bar With Cancer Data
Merus appears to have cleared the bar set by Wall Street for its highly watched cancer-treatment candidate. The company posts an abstract for its head and neck cancer treatment on Thursday, boasting a 60% response rate and one complete response in a pool of 10 evaluable patients. William Blair analysts say in a research note that the early dataset is a clear encouraging sign on the potential treatment's efficacy.